Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
暂无分享,去创建一个
K. Zaman | J. Sehouli | A. Leary | A. Awada | D. Castellano | V. Moreno | V. Alfaro | C. Kahatt | V. Subbiah | R. Kristeleit | A. Oaknin | J. Delord | A. Santaballa | M. Siguero | A. Zeaiter | C. Fernandez | G. Shappiro | Daniel Rueda
[1] B. Slomovitz,et al. Immunotherapy in endometrial cancer , 2023, International Journal of Gynecological Cancer.
[2] A. Awada,et al. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. , 2022, European journal of cancer.
[3] A. Tinker,et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.
[4] V. Moreno,et al. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study , 2021, International Journal of Gynecological Cancer.
[5] I. Vergote,et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). , 2021, Gynecologic oncology.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[8] I. Ray-Coquard,et al. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[10] I. Vergote,et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. , 2015, Gynecologic oncology.
[11] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[12] Juan A. Bueren-Calabuig,et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity , 2010, British journal of pharmacology.
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.